Experimental studies on preventive effects of API0134 on vessel reocclusion after thrombolysis.

Abstract

24 model rabbits with femoral arterial thrombosis were divided into two groups: the treatment group consisting of 12 rabbits which received API0134, and the control group composed of another 12 rabbits. 2 hours after recanalization by urokinase thrombolysis, reocclusion occurred only in 1/12 vessel (8%) with incomplete occlusion in the treated group, but in 8/12 (67%) with complete occlusion in the control group as assessed by angiograsphy. Pathological examination of specimen taken 24 hours after thrombolysis showed that 6/12 (50%) of the treated group gave the evidence of thrombus occlusion, and milder intimal injury and less adhered blood cells than in the control group, 83% of which had thrombus occlusion. In comparision with the control group, the function of platelet in the treated group demonstrated lower platelet aggregation rate (PAgR) and plasma thromboxane A2 (TXA2) level, higher prostacyclin (PGI2) and plasminogen activator (PA) activity as well as lower plasminogen activator inhibitor (PAI) activity. From the above it may be concluded that the preventive effect of API0134 on reocclusion might be due to inhibition of platelets aggregation and promotion of fibrinolysis.

• Authors: Y L Xiong, H Y Zhao
• Journal: Journal of Tongji Medical University = Tong ji yi ke da xue xue bao (J Tongji Med Univ) Vol. 15 Issue 2 Pg. 77-81 ( 1995) ISSN: 0257-716X [Print] China
• PMID: 8731957 (Publication Type: Journal Article)

Chemical References

• Drugs, Chinese Herbal
• Platelet Aggregation Inhibitors
• API 0134
• Thromboxane B2
• 6-Ketoprostaglandin F1 alpha
• Urokinase-Type Plasminogen Activator

Topics

• 6-Ketoprostaglandin F1 alpha (blood)
• Animals
• Drugs, Chinese Herbal (therapeutic use)
• Femoral Artery
• Male
• Platelet Aggregation (drug effects)
• Platelet Aggregation Inhibitors (therapeutic use)
• Rabbits
• Thrombolytic Therapy
• Thrombosis (drug therapy, prevention & control)
• Thromboxane B2 (blood)
• Urokinase-Type Plasminogen Activator (therapeutic use)